🔗 Share this article

The Nobel Prize in Physiology or Medicine was granted for transformative discoveries that clarify how the immune system targets dangerous pathogens while protecting the healthy tissues.

Three renowned researchers—from Japan Shimon Sakaguchi and American experts Mary Brunkow and Fred Ramsdell—received this accolade.

Their work uncovered specialized "security guards" within the defense system that eliminate rogue immune cells that could attacking the organism.

These discoveries are now paving the way for innovative treatments for autoimmune diseases and malignancies.

These laureates will share a monetary award worth 11 million Swedish kronor.

Crucial Discoveries

"Their research has been decisive for understanding how the immune system operates and why we do not all develop severe autoimmune diseases," stated the head of the Nobel Committee.

This trio's studies explain a core mystery: In what way does the defense system defend us from countless invaders while leaving our healthy cells intact?

Our immune system employs immune cells that scan for signs of infection, even viruses and germs it has never encountered.

These defenders utilize sensors—called recognition units—that are produced randomly in a vast number of variations.

This gives the defense network the capacity to fight a broad range of invaders, but the unpredictability of the process inevitably creates white blood cells that can attack the host.

Protectors of the Body

Researchers earlier understood that a portion of these problematic defense cells were eliminated in the immune organ—the site where white blood cells mature.

This year's Nobel Prize recognizes the discovery of T-reg cells—described as the immune system's "security guards"—which patrol the body to disarm any immune cells that attack the body's own tissues.

We know that this process fails in autoimmune diseases such as juvenile diabetes, multiple sclerosis, and rheumatoid arthritis.

The prize committee stated, "These findings have established a novel area of investigation and accelerated the development of innovative treatments, for instance for cancer and autoimmune diseases."

Regarding malignancies, T-regs prevent the system from fighting the tumor, so studies are aimed at reducing their quantity.

For self-attack disorders, trials are testing increasing regulatory T-cells so the organism is no longer being harmed. A similar approach could also be effective in reducing the risks of organ transplant rejection.

Pioneering Studies

Professor Sakaguchi, from Osaka University, conducted tests on mice that had their thymus extracted, leading to self-attack conditions.

The researcher demonstrated that introducing immune cells from healthy animals could stop the disease—implying there was a system for blocking defenders from harming the host.

Mary Brunkow, affiliated with the a research center in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in a California city, were studying an inherited autoimmune disease in rodents and humans that resulted in the identification of a genetic factor critical for the way regulatory T-cells operate.

"The pioneering work has revealed how the immune system is controlled by regulatory T cells, stopping it from accidentally targeting the healthy cells," said a leading physiology specialist.

"The work is a remarkable illustration of how fundamental physiological study can have broad consequences for public health."